香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全 部 或 任 何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 截至二零二三年六月三十日止六個月之 中期業績公告 杭 州 啓 明 醫 療 器 械 股 份 有 限 公 司（「本公司」或「公 司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至 二 零 二 三 年 六 月 三 十 日 止 六 個 月 之未經審核綜合中期業績，連同二零二二年同期之比較數字。 財務概要 截 至截 至 二零二三年二零二二年 六月三十日六月三十日 | --- | --- | --- | |--------------|--------------|----------| | 止六個月 | 止六個月 | 同比變動 | ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 （股份代號：250） （於香港註冊成立之有限公司） 中國數碼信息有限公司 截 至2023年6月30日 止 六 個 月 之 未 經 審 核 中 期 業 績 公 告 中 期 業 績 中 國 數 碼 信 息 有 限 公 司（「本 公 司」）董 事 會（「董 事 會」）謹 此 宣 佈 本 公 司 及 其 附 屬 公 司（「本 集 團」）截 至2023年6月30日 止 六 個 月 之 未 經 審 核 綜 合 業 績， 連 同2022年 之 比 較 數 字 如 下： – 1 – 簡 明 綜 合 收 益 表 截 至2023年6月30日 止 六 個 月 | --- | --- | --- | |-------|-------------- ...

目錄 | 2 | 公司資料 | | --- | --- | | 3 | 董事長致辭 | | 5 | 財務摘要 | | 6 | 管理層討論與分析 | | 44 | 董 事、監 事 及 高 級 管 理 層 | | 53 | 董事會報告 | | 81 | 企業管治報告 | | 108 | 環 境、社 會 及 管 治 報 告 | | 154 | 獨立核數師報告 | | 161 | 綜合損益及其他全面收益表 | | 163 | 綜合財務狀況表 | | 165 | 綜合權益變動表 | | 166 | 綜合現金流量表 | | 169 | 財務報表附註 | | 300 | 釋 義 | 公司資料 | 中文名稱： | 杭州啓明醫療器械股份有限公司 | | --- | --- | | 英文名稱： | Venus Medtech（Hangzhou）Inc. | | 法定代表： | 曾敏先生 | | 董事長： | 曾敏先生 | | 註冊資本： | 人民幣441,011,443元1 | | 中國總部： | | | 註冊及辦事處地址 | 中國杭州濱江區江陵路88號2幢3樓311室 | | 公司網址 | http://www.venusme ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全 部 或 任 何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 截至二零二二年十二月三十一日止年度之 年度業績公告 杭 州 啓 明 醫 療 器 械 股 份 有 限 公 司（「本公司」或「公 司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度（「報告期」）之 經 審 核 綜 合 業 績，連 同 二 零 二 一 年 同 期 之 經 審 核 比 較 數 字。 財務概要 截至二零二二年截至二零二一年 十二月三十一日十二月三十一日 止年度止年度 同比變動 人民幣千元 人民幣千元 | --- | --- | --- | --- | |-- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對 因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 中 國 數 碼 信 息 有 限 公 司 （於香港註冊成立之有限公司） （股份代號：250） 截 至2022年12月31日 止 年 度 之 未 經 審 核 年 度 業 績 公 告 業績 中國數碼信息有限公司（「本公司」）之董事會（「董事會」）謹此宣佈本公司及 其附屬公司（「本集團」）截至2022年12月31日止年度之未經審核年度業績， 該 年 度 業 績 乃 基 於 本 公 司 之 未 經 審 核 綜 合 管 理 帳 目，連 同 截 至2021年12 月31日止年度之可比較未經審核數字。 根 據 本 公 告「審 閱 未 經 審 核 年 度 業 績」一 段 所 述 之 原 因，本 集 團 截 至2021 年12月31日 止 年 度 之 年 度 業 績 的 審 核 程 序 尚 未 完 成 及 截 至2022年12月31 日止年度之年度業績審核程序尚未開始，本公司無法根據香港聯合交易 所有限公司證券上市規則（ ...

杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （於中華人民共和國註冊成立的股份有限公司) 股份代號：2500 2022 中期報告 目錄 2 公司資料 4 財務摘要 5 管理層討論與分析 28 企業管治及其他資料 45 中期簡明綜合損益及其他全面收益表 47 中期簡明綜合財務狀況表 49 中期簡明綜合權益變動表 51 中期簡明綜合現金流量表 54 中期簡明綜合財務資料附註 82 釋 義 公司資料 （截 至 二 零 二 二 年 六 月 三 十 日） | 中文名稱： | 杭州啓明醫療器械股份有限公司 | | --- | --- | | 英文名稱： | Venus Medtech （Hangzhou） Inc. | | 法定代表： | 曾敏先生 | | 董事長： | 曾敏先生 | | 註冊資本： | 人民幣441,011,443元 | | 中國總部： | | | 註冊辦事處地址： | 中國杭州濱江區江陵路88號2幢3樓311室 | | 公司網址： | http://www.venusmedtech.com/ | | 電郵： | inquiry@venusmedtech.co ...

Financial Performance - Revenue for the six months ended June 30, 2022, was HK$507,552,000, representing a 14% increase from HK$445,208,000 in the same period of 2021[6] - Gross profit increased to HK$425,221,000, up 20% from HK$354,501,000 year-over-year[6] - Profit attributable to owners of the Company for the period was HK$7,208,000, compared to a loss of HK$35,013,000 in the previous year[10] - Basic and diluted earnings per share for the period were HK$0.04, a recovery from a loss of HK$0.18 per share in the same period last year[6] - Total comprehensive income for the period was a loss of HK$6,391,000, an improvement from a loss of HK$35,854,000 in the prior year[10] - The total comprehensive income for the period was a loss of HK$6,391,000, compared to a loss of HK$35,854,000 for the same period in 2021, indicating a 82.2% improvement[26] - The profit for the period was HK$7,208,000, a positive shift from a loss of HK$35,013,000 in the same period of 2021[21] - Other operating income increased to HK$80,276,000 from HK$64,547,000, marking a growth of about 24% year-over-year[61] - The reportable segment loss before income tax improved to HK$45,358,000 from HK$75,863,000, reflecting a reduction in losses of approximately 40%[54] - The revenue from the digital business and information technology services segment was approximately HK$35.7 million, with a loss before income tax of approximately HK$28.1 million during the reporting period[128] Assets and Liabilities - Non-current assets decreased to HK$2,248,953,000 from HK$2,222,473,000 as of December 31, 2021[13] - Current liabilities totaled HK$916,589,000, down from HK$955,285,000 at the end of 2021[15] - Net assets increased to HK$1,520,293,000 from HK$1,456,943,000 as of December 31, 2021[15] - The Group reported net current liabilities of approximately HK$651,500,000 as of June 30, 2022[40] - Reportable segment assets as of June 30, 2022, totaled HK$1,247,414,000, down from HK$1,320,473,000 as of December 31, 2021, representing a decrease of about 5.5%[56] - Reportable segment liabilities decreased to HK$747,584,000 from HK$778,463,000, indicating a reduction of approximately 4%[56] Cash Flow - For the six months ended June 30, 2022, the net cash used in operating activities was HK$7,567,000, a significant improvement compared to HK$99,147,000 for the same period in 2021, representing an 92.4% decrease[18] - The net cash used in investing activities was HK$6,771,000, a decline from the cash generated of HK$182,517,000 in the previous year[18] - The net cash used in financing activities was HK$27,084,000, compared to cash generated of HK$65,345,000 in the prior year[18] - Cash and cash equivalents decreased to HK$48,681,000 at June 30, 2022, down from HK$416,039,000 at the beginning of the year, marking an 88.3% decline[18] - The Group's cash and cash equivalents were approximately HK$48.7 million as of June 30, 2022, down from approximately HK$92.7 million as of December 31, 2021[134] Segment Performance - For the six months ended June 30, 2022, the total revenue from reportable segments was HK$507,552,000, representing an increase of 14% compared to HK$445,208,000 in the same period of 2021[54] - Revenue from enterprise cloud services was HK$471,816,000, up from HK$445,208,000, indicating a growth of 6% year-over-year[58] - The digital business and information technology services segment generated revenue of HK$35,736,000, which was a new addition as there was no revenue reported in the same period last year[58] Employee and Management - The Group's total employee salaries and allowances for the six months ended June 30, 2022, were approximately HK$363.6 million, compared to approximately HK$359.4 million for the same period in 2021, reflecting a slight increase of 0.6%[142] - As of June 30, 2022, the Group employed approximately 4,351 employees, a decrease from 5,531 employees as of June 30, 2021, indicating a reduction of about 21.4%[142] - The Group focuses on providing skill and quality training for employees, emphasizing on-the-job capability training and personal work attitude[142] - The Group's employee remuneration policy includes basic salary, housing benefits, and contributions to mandatory provident funds, among other benefits[142] Corporate Governance and Compliance - The company has complied with the Corporate Governance Code throughout the six months ended June 30, 2022, except for delays in issuing audited annual results and convening the annual general meeting[176][180] - The Company has adopted the Model Code for Securities Transactions by Directors and confirmed compliance by all directors for the six months ended June 30, 2022[192] - Trading in the Company's shares on the Hong Kong Stock Exchange has been suspended since April 1, 2022, pending fulfillment of Resumption Guidance[200] Share Capital and Dividends - The company did not declare or pay any dividends during the six months ended June 30, 2022, consistent with the same period in 2021[72] - The company maintained the same number of issued and fully paid ordinary shares at 21,720,504,877 as of June 30, 2022, with a share capital of HK$240,597,000[86] - The Company’s share option scheme lapsed on May 28, 2022, indicating a shift in employee incentive strategies[142] Loans and Financial Obligations - As of June 30, 2022, the outstanding principal and accrued interests of the loan to Nan Hai are approximately HK$758,996,000 and HK$60,886,000 respectively, with an interest rate of 8% per annum[184][186] - The Digital Huigu Loan is subject to an interest rate of 8% per annum, with a default interest rate of 10% per annum on any overdue amounts[190] - The repayment due date for the Digital Huigu Loan has been extended to June 20, 2024, following a supplemental agreement made on April 7, 2021[190] Market and Product Development - CE Dongli launched the 2022 global portal foreign trade professional edition, which supports 42 languages and has achieved industry-leading performance in Google search engine optimization[124] - The new global portal marketing professional edition features enhanced automatic website optimization capabilities, significantly improving digital marketing automation for clients[123] - The loading speed of clients' websites using the new foreign trade edition is more than double that of top competitors in the industry, ensuring better performance[124] - The Group has established a nationwide localized service network to effectively address the "last kilometer" issue in delivering SaaS solutions to corporate clients[110] - CE Dongli's digital marketing products cater to a wide range of clients, from large enterprises to small and micro-sized businesses, demonstrating a complete product spectrum[118]

Company Overview and Strategy - The company has implanted over 9,000 TAVR products since their launch, with VenusA-Valve being the only product in China with 9 years of follow-up data[10]. - In January 2022, the company completed the acquisition of Cardiovalve, which focuses on innovative therapies for mitral and tricuspid valve diseases, indicating significant market potential[11]. - The company aims to enhance its international brand influence through the commercialization of VenusP-Valve in the EU[11]. - The company is committed to high-quality innovation and strategic planning to improve its competitiveness in the medical device industry[13]. - The company emphasizes the importance of innovation and internationalization in response to the challenges faced in the medical industry[9]. - The company is recognized as a leading enterprise in the field of minimally invasive treatment for structural heart disease in China[10]. - The company is focused on developing and commercializing innovative medical devices for structural heart disease[10]. - The company anticipates achieving strategic milestones to benefit more patients globally[11]. - The company has established a comprehensive solution for structural heart disease, covering various heart valve diseases and related procedures[10]. Financial Performance - Revenue for 2021 reached RMB 415,862 thousand, a significant increase of 50.7% compared to RMB 276,047 thousand in 2020[15]. - Gross profit for 2021 was RMB 324,344 thousand, up 42.7% from RMB 227,280 thousand in 2020[15]. - The company reported a pre-tax loss of RMB 377,555 thousand in 2021, worsening from a loss of RMB 185,843 thousand in 2020[15]. - Total non-current assets increased to RMB 1,669,835 thousand in 2021, compared to RMB 957,794 thousand in 2020, reflecting a growth of 74.3%[17]. - Current assets totaled RMB 3,439,622 thousand in 2021, slightly up from RMB 3,360,433 thousand in 2020[17]. - VenusA-Valve and VenusA-Plus generated sales revenue of RMB 405.3 million for the year ending December 31, 2021, representing a 49% increase from RMB 272.0 million for the year ending December 31, 2020[29]. - The company's total revenue for the year ended December 31, 2021, was approximately RMB 415.9 million, an increase of 50.7% compared to RMB 276.0 million for the year ended December 31, 2020[78]. - Sales from VenusA-Valve and VenusA-Plus accounted for 97.4% of total revenue, generating RMB 405.3 million, compared to 98.5% in the previous year[81]. Product Development and Innovation - The company has established a product pipeline consisting of 14 innovative devices, including two marketed TAVR products, VenusA-Valve and VenusA-Plus[21]. - The company is focusing on developing new materials, biomimetics, imaging integration technology, and digital sensing to enhance its product offerings[19]. - VenusP-Valve has completed clinical trials in both the European Union and China, with CE mark certification expected in 2022[31]. - Long-term clinical studies for VenusP-Valve demonstrated a 100% procedural success rate and a 5-year postoperative mortality rate of only 3.64%[34]. - Venus-PowerX, a new generation TAVR product, completed its first-in-man clinical trial on December 21, 2021[37]. - Venus-Vitae, another new generation TAVR system, successfully completed its first two FIM clinical implants in Argentina on December 16, 2021[41]. - The company emphasizes that it may not ultimately succeed in developing and marketing VenusA-Valve, VenusA-Plus, VenusP-Valve, Venus-PowerX, and Venus-Vitae[30][36][40][42]. Acquisitions and Partnerships - Cardiovalve acquisition completed for $266 million, with milestone-based conditional payments[44]. - The company plans to accelerate clinical development and registration in the Chinese market post-Cardiovalve acquisition[46]. - Liwen RF acquisition for a maximum price of RMB 493 million, aimed at enhancing treatment options for HCM patients[56]. - The company has signed a strategic cooperation framework agreement with United Family Healthcare to establish treatment collaboration for VenusA-Valve and VenusA-Plus, enhancing patient care for heart valve diseases[28]. - The company actively collaborates with leading innovative medical device companies and academic institutions to enhance its product pipeline and maintain a competitive edge in structural heart disease technology[62]. - The company has established the Venus Global Heart Valve Innovation Center in Israel to focus on breakthrough innovative therapeutic technologies, including the development of next-generation aortic regurgitation treatment technologies[63]. Research and Development - The company's R&D expenses were RMB 167.3 million and RMB 258.3 million for the years ended December 31, 2020, and December 31, 2021, respectively, indicating a year-over-year increase of 54.3%[64]. - As of February 28, 2022, the company held a total of 756 patents and patent applications, including 315 granted invention patents, with 284 applications in China and 445 overseas[65]. - The company has made significant contributions to the clinical trials and registration of TMVR and TPVR products, such as VenusA-Valve and VenusP-Valve[160]. Risk Factors - The company has identified several key risks, including those related to product development, government regulations, commercialization, production, and reliance on third parties[129]. - The company has incurred net losses since its establishment and may continue to do so in the foreseeable future, posing a high risk to potential investors[130]. - Future growth is largely dependent on the success of product development; significant delays in clinical development or regulatory approval could severely impact the business[130]. - The clinical product development process is lengthy and costly, with uncertain outcomes; failures in clinical trials could have a major adverse effect on future prospects[132]. - Regulatory approvals are critical for commercialization; delays or failures in obtaining necessary approvals could severely impair revenue generation capabilities[132]. - The company faces significant competition, which may lead to others successfully developing or commercializing competitive products before it does[134]. - The company relies on a limited number of suppliers; any loss of qualification or contractual disputes could severely damage operations[137]. - The company’s goodwill constitutes a significant portion of its total assets, and any impairment could adversely affect its financial condition[143]. Governance and Management - The company has a strong governance structure with independent directors providing oversight on major decisions and management performance[182]. - The company emphasizes compliance with listing rules and corporate governance standards in its operations[184]. - The company is focused on maintaining financial oversight and monitoring the performance of its directors and senior management[186]. - The company is committed to maintaining high standards of financial management and oversight through its appointed executives[198].

Financial Performance - The company reported a total revenue of HKD 1,016,061,000 for the year ended December 31, 2021, representing an increase from HKD 972,139,000 in 2020, which is approximately a 4.5% growth[5]. - The gross profit for the year was HKD 822,916,000, slightly up from HKD 818,151,000 in the previous year, indicating a stable gross margin[5]. - The company incurred a net loss attributable to shareholders of HKD 107,960,000 for the year, compared to a profit of HKD 111,014,000 in 2020, reflecting a significant decline in profitability[5]. - Operating expenses increased to HKD 715,690,000 from HKD 526,526,000, marking a rise of approximately 36% year-over-year[5]. - The company reported other operating income of HKD 127,073,000, down from HKD 135,024,000 in the previous year, indicating a decrease of about 5.3%[5]. - The company’s comprehensive loss for the year was HKD 101,781,000, compared to a comprehensive income of HKD 115,344,000 in 2020, indicating a shift in overall financial performance[7]. - The company’s basic and diluted loss per share was HKD 0.54, a decline from earnings per share of HKD 0.56 in the previous year[5]. - The foreign exchange gain from overseas operations was HKD 5,759,000, up from HKD 3,541,000, reflecting improved currency management[7]. Assets and Liabilities - Total assets decreased from HKD 1,589,369,000 in 2020 to HKD 1,544,064,000 in 2021, representing a decline of approximately 2.8%[9]. - The company's total liabilities increased from HKD 688,932,000 in 2020 to HKD 955,285,000 in 2021, indicating a rise of about 38.7%[10]. - The net asset value decreased from HKD 1,556,589,000 in 2020 to HKD 1,456,943,000 in 2021, reflecting a reduction of approximately 6.4%[10]. - The company's equity decreased from HKD 1,315,992,000 in 2020 to HKD 1,216,346,000 in 2021, a decline of about 7.5%[10]. - The company reported a cash and cash equivalents balance of HKD 92,698,000 in 2021, down from HKD 265,080,000 in 2020, a decrease of approximately 65%[9]. - The company’s total liabilities to total assets ratio increased from approximately 43.3% in 2020 to 61.8% in 2021, indicating a higher leverage position[10]. - The company’s retained earnings decreased from HKD 1,315,992,000 in 2020 to HKD 1,216,346,000 in 2021, a decline of about 7.5%[10]. - The company reported a significant increase in deferred tax liabilities from HKD 2,771,000 in 2020 to HKD 57,522,000 in 2021, reflecting a rise of approximately 1940%[10]. Revenue Segments - Revenue from bundled services was HKD 732,781,000 in 2021, down from HKD 809,961,000 in 2020, indicating a decline of about 9.5%[23]. - Internet infrastructure services revenue increased significantly to HKD 161,376,000 in 2021 from HKD 78,086,000 in 2020, marking a growth of approximately 106.5%[23]. - The total revenue from external customers for the "Enterprise Cloud Services" segment in 2021 was HKD 972,008,000, compared to HKD 972,139,000 in 2020, indicating a slight decrease of 0.01%[28]. - The "Digital Business and Information Technology Services" segment reported no revenue in 2021, while the total revenue for the reportable segments was HKD 1,038,798,000 in 2021, up from HKD 972,139,000 in 2020, reflecting an increase of 6.8%[28]. Acquisitions and Investments - The company completed the acquisition of 100% equity in Digital Star Technology Development (Beijing) Co., Ltd. for RMB 488 million (approximately HKD 585.9 million) on July 26, 2021[46]. - The company completed the acquisition of Chenxing Technology Group on July 26, 2021, enhancing its digital commerce and information technology services[54]. - The goodwill recognized from the acquisition was HKD 323,247,000[50]. - The acquisition of Chenxing Technology was completed on July 26, 2021, for a price of RMB 488 million, which will be consolidated into the company's financial statements[67]. Future Outlook and Strategy - The company anticipates generating positive operating cash flow in 2022, ensuring sufficient resources to meet its working capital and other financing needs[16]. - The company expects that the new amendments to the Hong Kong Financial Reporting Standards will not have a significant impact on its consolidated financial performance[22]. - The company anticipates continued growth in enterprise cloud services and ticket management system services in the upcoming fiscal year[24]. - The company has plans for market expansion and new product development to enhance its service offerings[23]. - The company is focused on improving operational efficiency and exploring potential mergers and acquisitions to drive future growth[23]. - The company is actively monitoring RMB exchange rate fluctuations, which may impact its financial performance, and has not entered into any foreign exchange hedging instruments during the year[75]. - Overall, the company remains optimistic about future growth, citing strong demand and a robust pipeline of products and services[91]. Employee and Governance - As of December 31, 2021, the company had 4,891 employees, a decrease from 5,418 employees in 2020[76]. - Total employee compensation and benefits amounted to approximately HKD 746.4 million for the year ended December 31, 2021, compared to approximately HKD 567.5 million in 2020, representing an increase of 31.5%[76]. - The company has adhered to applicable corporate governance codes throughout the year ended December 31, 2021, with minor deviations noted[80]. - The audit committee consists of all independent non-executive directors, ensuring oversight of the financial reporting process[82]. Financial Reporting and Compliance - The company is currently undergoing a review process for its annual performance, which has not yet been completed, delaying the publication of the audited financial results[3]. - The financial statements are prepared based on the Hong Kong Financial Reporting Standards, which include applicable individual standards and interpretations[14]. - The company plans to issue its annual report by April 30, 2022, which will include all information required by the listing rules[89]. - The company expects no significant deviation between the unaudited financial results and the audited results for the year ended December 31, 2021[86].

杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （於中華人民共和國註冊成立的股份有限公司) 股份代號：2500 2021 中期報告 目錄 2 公司資料 4 財 務 摘 要 5 管理層討論與分析 27 企業管治 及 其他資料 41 中期簡明綜合損益及其他全面收益表 43 中期簡明綜合財務狀況表 45 中期簡明綜合權益變動表 47 中期簡明綜合現金流量表 50 中期簡明綜合財務資料附註 68 釋 義 公司資料 （截至二零二一年六月三十日） | 中文名稱： | 杭州啓明醫療器械股份有限公司 | | --- | --- | | 英文名稱： | Venus Medtech (Hangzhou) Inc. | | 法定代表： | 曾敏先生 | | 董事長： | 曾敏先生 | | 註冊資本： | 人民幣441,011,443元 | | 中國總部： | | | 註 冊 辦事處地址： | 中國杭州濱江區江陵路88號2幢3樓311室 | | 公司網址： | http://www.venusmedtech.com/ | | 電 郵： | inquiry@venusmedtech.com | ...